Trodelvy: Targeting Tumors with Precision- A Deep Dive into its Mechanism And Impact

Trodelvy  (sacituzumab govitecan-hziy) is prescribed for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). This includes those who have undergone two or more prior systemic therapies, with at least one specifically for metastatic disease. Additionally, Trodelvy is indicated for the treatment of locally advanced or metastatic urothelial cancer (mUC) in individuals who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PDL1) inhibitor.

It is a targeted therapy that works by exploiting the presence of Trop-2, a cell surface antigen, in cancer cells. The drug is an antibody-drug conjugate (ADC) composed of a humanized antibody that recognizes Trop-2 and a small molecule, SN-38, which is a topoisomerase I inhibitor.

The mechanism of action of Trodelvy involves the following steps:

1. Targeting Trop-2: Sacituzumab is a humanized antibody that specifically recognizes Trop-2, a cell surface antigen overexpressed in many types of cancer cells, including triple-negative breast cancer.

2. Internalization: Once the drug binds to Trop-2-expressing cancer cells, it is internalized into the cells.

3. Release of SN-38: Inside the cancer cells, the SN-38 molecule is released, which prevents the re-ligation of topoisomerase I, an enzyme involved in DNA replication.

4. Inhibition of DNA Replication: The accumulation of SN-38 in cancer cells leads to the inhibition of DNA replication, causing cancer cell death.

Trodelvy (sacituzumab govitecan-hziy) for injection is available in the form of a lyophilized powder for intravenous use. Each single-dose vial contains 180 mg of the lyophilized powder, which requires reconstitution before administration.

The clinical benefits of Trodelvy are supported by research showing its effectiveness in inhibiting tumor growth in mouse xenograft models of triple-negative breast cancer. Trodelvy has been shown to shrink tumors and reduce the risk of cancer progression in patients with triple-negative breast cancer. However, it is essential to note that individual patient responses and treatment decisions should always be made in consultation with a healthcare professional.

Availability:

If you are looking to buy Trodelvy online, which is available only in US and Europe. You can prioritize reaching out to Sansfro Health. Sansfro Health is committed to streamlining the importation process and delivering accurate pricing information to ensure a seamless experience for individuals seeking this medication. Sansfro can facilitate the importation of the medication, providing genuine pricing and comprehensive support. To inquire about the price of Trodelvy in India and gain insights into the importing procedure, individuals can reach out to the Patient Support Team at (+91) 93157 05373 or via email at help@sansfro.com.   

Reference

1. https://www.Trodelvy.com/patient/mtnbc/how-it-works 
2. https://www.Trodelvyhcp.com/moa 
3. https://www.askgileadmedical.com/docs/Trodelvy/Trodelvy-mechanism-of-action 
4. https://www.ema.europa.eu/en/medicines/human/EPAR/Trodelvy